HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host's immune response. Hepatitis C virus is classified into six genotypes(1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6).
The E.coli derived recombinant protein contains the HCV core nucleocapsid immunodominant regions, amino acids 2-119.
The protein is fused to a GST tag at N-Terminus.
Protein is >95% pure as determined by 10% PAGE (coomassie staining).
25mM Tris-HCl, pH 8.0, 1.5M Urea, 0.2% Triton-X and 50% glycerol.
HCV Core Genotype-2b although stable at 4°C for 1 week, should be stored below -18°C.
Please prevent freeze thaw cycles.
Immunoreactive with sera of HCV-infected individuals.
Antigen in ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.